Cell therapy weekly: US FDA removes clinical hold on gene therapy program for hemophilia B

This week: the US FDA has removed the clinical hold on uniQure’s hemophilia B gene therapy program, in addition to clearing an IND application for a gene therapy candidate termed ‘VY-HTT01’ for Huntington’s disease; and the UK’s first clinical trial-focused viral vector manufacturer announces their official launch. The news highlights: US FDA removes clinical hold on gene therapy program for hemophilia B US FDA clears IND application for gene therapy candidate VY-HTT01 for Huntington’s disease UK’s first clinical trial-focused viral vector manufacturer announces official launch   US FDA removes clinical hold on gene therapy program for hemophilia B uniQure (Amsterdam,...